05:02 AM EDT, 07/30/2024 (MT Newswires) -- Verastem ( VSTM ) said Monday that the US Food and Drug Administration has granted orphan drug designation to avutometinib in combination with defactinib for the potential treatment of pancreatic cancer.

This comes after the company reported positive initial interim results from the ongoing RAMP 205 trial evaluating avutometinib and defactinib in combination with the standard of care chemotherapy in first-line metastatic pancreatic cancer.

The company said it expects to report updated data from the RAMP 205 trial in Q1 of 2025.

Verastem's ( VSTM ) share price rose more than 7% after-market hours on Monday.

Price: 2.9500, Change: +0.21, Percent Change: +7.66